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OBJECTIVE: To analyze surgical and pathological parameters and outcome and prognostic factors of patients with
nonsmall cell lung cancer (NSCLC) who were admitted to a single institution, as well as to correlate these findings to the
current staging system.
METHOD: Seven hundred and thirty seven patients were diagnosed with NSCLC and admitted to Hospital do Cancer
A. C. Camargo from 1990 to 2000. All patients were included in a continuous prospective database, and their data was
analyzed. Following staging, a multidisciplinary team decision on adequate management was established. Variables included
in this analysis were age, gender, histology, Karnofsky index, weight loss, clinical stage, surgical stage, chemotherapy,
radiotherapy, and survival rates.
RESULTS: 75.5% of patients were males. The distribution of histologic type was squamous cell carcinoma 51.8%,
adenocarcinoma 43.1%, and undifferentiated large cell carcinoma 5.1%. Most patients (73%) presented significant weight
loss and a Karnofsky index of 80%. Clinical staging was IA 3.8%, IB 9.2%, IIA 1.4%, IIB 8.1%, IIIA 20.9%, IIIB 22.4%, IV
30.9%. Complete tumor resection was performed in 24.6% of all patients. Surgical stage distribution was IA 25.3%, IB 1.4%,
IIB 17.1%, IIIA 16.1%, IIIB 20.3%, IV 11.5%. Chemotherapy and radiotherapy were considered therapeutic options in 43%
and 72%, respectively. The overall 5-year survival rate of nonsmall cell lung cancer patients in our study was 28%. Median
survival was 18.9 months.
CONCLUSIONS: Patients with NSCLC who were admitted to our institution presented with histopathologic and
clinical characteristics that were similar to previously published series in cancer hospitals. The best prognosis was associated
with complete tumor resection with lymph node dissection, which is only achievable in earlier clinical stages.
KEY WORDS: Lung cancer. Nonsmall cell carcinoma. Prognostic factors. Staging. Treatment outcome.
In the past few years, lung cancer
has become the most prevalent and ag-
gressive cancer in the world. In the
United States, malignant pulmonary
tumors account for more deaths than
any other type of cancer, including fe-
male breast cancer. The same is true for
Europe, where lung cancer is respon-
sible for nearly 28% of all deaths due
to cancer.1 In Brazil, it is estimated that
in 2002, 18000 deaths have occurred
due to lung cancer.2
Smoking is considered the main
factor in the genesis of lung cancer.3 It
is estimated that approximately one
third of the Brazilian adult population
smokes, resulting in an extremely large
number of people at high risk of de-
veloping tumors of the upper respira-
tory and digestive tracts, especially in
the lungs.2
Pulmonary carcinoma has been
classically divided into 2 histological
groups as a result of the clearly dis-
tinct biological behavior: small cell
(SCLC) and nonsmall cell lung cancer
(NSCLC). The latter occurs in 70% to
80% of all patients.1 It is estimated
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that 75% of these patients present lo-
cally advanced or metastatic disease at
the time of diagnosis.1,4
The outcome for patients with
NSCLC is directly related to the stage
of disease, as well as to the treatment
strategy. Most studies present data
originating from randomized or strictly
controlled prospective trials. Retro-
spective series generally include chart
reviews of patients admitted over a
long period of time, usually decades,
with the obvious implications of ma-
jor differences over time of staging
methods, treatment strategies,
perioperative surgical care, as well as
different chemotherapy and radio-
therapy regimens and methods.
The present study presents data
from a prospective database on con-
secutive patients admitted with
NSCLC between 1990 and 2000 in a
single institution in Brazil. Clinical,
surgical, and pathological parameters
as well as outcomes of the patients are
analyzed, and prognostic factors
aredetailed. Correlation with the cur-
rent staging system is performed.
MATERIALS AND METHOD
Between 1990 and 2000, 1132 pa-
tients were evaluated at the Depart-
ment of Thoracic Surgery of Hospital
do Câncer AC Camargo with diag-
nosed lung cancer. Of these, 840 were
admitted for complete management,
which included diagnostic review and
confirmation of histologic type, clini-
cal staging, and treatment. The other
292 patients were excluded from the
analysis for the following reasons:
unavailable biopsy for reconfirmation
of the diagnosis, treated elsewhere, or
lost from follow-up before any inter-
vention in our hospital. Most patients
(n = 737) presented with NSCLC that
was confirmed by the Pathology De-
partment from cytology or histology
specimens from different sources: bron-
choscopy, trans-thoracic needle bi-
opsy, or incisional or excisional bi-
opsy of the primary tumor or its
metastases. All patients were included
in a continuous prospective database,
and their data was analyzed. The stag-
ing routine in our department in-
cluded CT scan of the thorax and up-
per abdomen, CT scan of the central
nervous system, and bone scan. Fol-
lowing clinical extrathoracic staging,
a multidisciplinary team decision on
adequate management was estab-
lished. Clinical status was routinely
determined by the evaluation of
pneumonologists and anesthe-
siologists as to the operative risks for
all patient candidates regarding opera-
tive procedures. Staging was deter-
mined according to the current system.
Whenever clinical status permitted,
routine management of NSCLC was as
follows: patients at stages I and II un-
derwent surgical resection of their pri-
mary tumor. Lobectomy or pneumon-
ectomy were considered standard pro-
cedures, with mediastinal lymph node
dissection. Resection was considered
complete whenever all margins of the
resected specimen were confirmed mi-
croscopically to be negative and the
highest mediastinal lymph node
resected was free of cancer spread. For
patients at resected stage IIIa, adjuvant
radiotherapy of the lung and mediasti-
num was indicated. Patients with
unresectable IIIa and IIIb tumors under-
went either radiotherapy alone or
chemoradiation. Patients at stage IV,
with no brain metastases, underwent
systemic chemotherapy. On the other
hand, patients with NSCLC and cen-
tral nervous system metastases under-
went whole brain radiation, followed
by palliative treatment for extra-cer-
ebral lesions. All patients were fol-
lowed up on a routine basis after com-
pletion of the treatment, with sched-
uled radiological and clinical evalua-
tions. Our follow-up policy consisted
of routine chest X-ray and medical
evaluation every 3 months for the first
2 years, then every 6 months until the
fifth year, then every year. No scans or
blood tests were performed unless the
clinical situation or new symptoms
warranted specific tests.
Statistical Analysis
Data on patients evaluated in this
study were collected and analyzed us-
ing the Statistical Package for the So-
cial Sciences (SPSS, Inc., Chicago, Il-
linois, USA).
Variables included in this analysis
were age, gender, histology, Karnofsky
index, weight loss, clinical stage, sur-
gical stage, chemotherapy, radio-
therapy, and survival rates determined
by the Kaplan-Meier survival curves.
Differences between groups were as-
sessed by the log-rank test and were
considered significant at P < 0.05.
RESULTS
Gender
Most patients (75.5%) with NSCLC
were males (Table 1) with age at ad-
mission ranging from 18 to 87.6 years
(median = 59.5 years).
Histology
The nonsmall cell lung cancer pa-
tients were classified as having squa-
mous cell carcinoma (51.8%), adeno-
carcinoma (43.1%), or undifferentiated
large cell carcinoma (5.1%). The use
of immunohistochemical methods for
diagnosis has lead to an increase in the
sensitivity and specificity of the diag-
nosis of both squamous cell carcinoma
and adenocarcinoma, decreasing the
number of undifferentiated large cell
carcinoma diagnoses.
In 61.2% of nonsmall cell lung
cancer patients, surgery was not per-
formed, reflecting the advanced stag-
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ing of the studied population. Of all
patients included in this study, only
24.6% had complete tumor resection.
On the other hand, 86.3% of the pa-
tients that underwent surgery with a
curative intent had their tumors com-
pletely resected.
Surgical Stage
Following surgery, staging is more
effective due to histologic confirma-
tion of the spread of the disease. Those
patients that had surgery were biased
towards a less aggressive stage (52.1%
were stages I or II). Many of the pa-
tients with clinical stages IIIB or IV
did not undergo surgery. The stage dis-
tribution of surgical patients was:
25.3% - IA (n = 72), 1.4% - IB (n = 4),
8.3% - IIA (n = 24) 17.1% - IIB (n =
49), 16.1% - IIIA (n = 6), 20.3% - IIIB
(n = 58), 11.5% - IV (n = 33). Patients
at stage IIIB and IV underwent surgery
in order to make pathologic confirma-
tion of the presence of distant
metastases, mediastinal invasion, or
pleural metastases.
Chemotherapy
Chemotherapy was indicated at
some point during treatment in 43% of
the patients.
Neoadjuvant Treatment
Neoadjuvant treatment was not
considered routine at any stage for
NSCLC patients in our institution.
Therefore, few patients (17%) received
any neoadjuvant therapy; these were
participating in clinical trials.
Choice of Chemotherapy
The chemotherapy drugs used and
the drug combinations employed in the
Hospital do Cancer between 1990 and
2000 reflected tendencies in cancer
centers around the world. Cisplatin or
carboplatin were established as the
standard treatment for the majority of the
patients. Lately, the introduction of
novel drugs, such as taxanes,
gemcitabine, and vinorelbine has sig-
nificantly expanded the prospects of sys-
temic treatment of nonsmall cell lung
cancer. Chemotherapy regimens most
commonly included: MVP (mitomycin,
vinblastin, and cisplatinum);
carboplatin and paclitaxel; and
vinorelbine, gemcitabine, and docetaxel
associated with a platinum-derived drug
(cisplatinum or carboplatinum) when-
ever clinically adequate.
Number of Drugs Used in
Chemotherapy
Most patients (48.3%) received a
combination of 2 drugs. A few (12.1%)
received only 1 drug, and 39.6% re-
ceived a regimen containing 3 drugs.
Chemotherapy Cycles
Patients routinely received 2
chemotherapy cycles, followed by an
evaluation of both tumor response to
therapy and the patient’s tolerance to
the treatment. Of the total number of
patients, 26.2% received 1 cycle of
chemotherapy and 22% received 2 cy-
cles. Upon confirmation of tumor re-
sponse and acceptable toxicity, pa-
tients received up to 6 cycles (20.1%
- 3 cycles, 11.3% - 4 cycles, 6.8% - 5
cycles, and 9.4% - 6 cycles). Rarely
were more than 6 cycles administered
(4.2%).
Radiotherapy
In total, 71.6% of the patients re-
ceived radiotherapy at any point dur-
ing treatment. Of these, only 3.1% re-
ceived neoadjuvant radiotherapy. A
larger group (19.1%) had adjuvant ra-
diotherapy following resection of the
primary tumor. All other patients re-
ceived radiation therapy as their pri-
mary treatment for the primary tumor
or its metastases.
Radiotherapy Dose
Most patients (56.5%) received
doses smaller than 5000 cGy (43.7%
received less than 4000 cGy and
12.8% between 4000 and 5000 cGy).
Another 28.4% received between 5000
and 6000 cGy, and 15.3% received
more than 6000 cGy. Three-dimen-
sional conformal radiotherapy was not
available in the Hospital do Câncer
A.C. Camargo during the period be-
tween 1990 and 2000.
Survival
The overall 5-year survival rate of
nonsmall cell lung cancer patients in
our study was 28%. Median survival
time was 18.9 months.
Prognostic factors for long-term
Table 1 - Patient characteristics at
admission.
Gender
Male
75.5%
Female 24.5%
Age (years)
< 50 9.7%
51-60 59.5%
61-70 26.6%
> 70 4.2%
Histology
Squamous cell carcinoma 51.8%
Adenocarcinoma 43.1%
Large cell carcinoma 5.1%
Karnofsky Index
< 70 3.8%
70 10.1%
80 65.4%
90 15.5%
100 5.1%
Weight Loss
≤ 10% 72.8%
> 10% 27.2%
Clinical Stage
IA 3.8%
IB 9.2%
IIA 1.4%
IIB 8.1%
IIIA 20.9%
IIIB 22.4%
IV 30.9%
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survival were evaluated in the patient
population (Table 2).
Survival is significantly associated
with clinical stage upon diagnosis (Fig-
ure 1) and surgical stage confirmed by
pathology analysis during surgery
(Figure 2). Weight loss significantly
affected long-term survival, mainly in
patients with extra-CNS metastases
(Figure 3).
Tumor histology (squamous cell,
adenocarcinoma, or undifferentiated
large cell) also had an impact on sur-
vival. Undifferentiated large cell car-
cinoma had a significantly lower sur-
vival rate than squamous cell carci-
noma and adenocarcinoma (P < 0.05).
Complete resection had a signifi-
cant impact on 5-year survival of pa-
tients with nonsmall cell lung cancer.
DISCUSSION
Lung cancer has been a widely
studied subject, especially due to its
high prevalence and poor prognosis,
particularly in advanced stages. Smok-
ing is classically associated with the
development of these tumors.3 Lung
cancer has a male predominance (both
regarding incidence and mortality)
that seems to be due to historically
higher levels of men who smoke, as
confirmed by our results. However, re-
cent data reveal increased incidence
and mortality of women with lung
cancer and a corresponding rise of the
number of smokers as well.2,5 Most pa-
tients with NSCLC are diagnosed at a
productive age, with limited long-term
prognosis for 5-year survival. Studies
in the literature, as well as our own re-
sults, confirmed that the highest inci-
dence of the disease is between 50 and
70 years of age, with a relatively lower
incidence in younger patients.2,6,7
The distribution of nonsmall cell
lung cancers by histologic type has
changed, as compared to the distribu-
tion in this same institution in the
Table 2 - Prognostic factors at overall 5-year survival rates.
Variable Median survival (months) P
Clinical Stage < 0.001
IA n.a
IB 95
IIA 78
IIB 73
IIIA 23
IIIB 16
IV 10
Histology 0.001
Squamous cell carcinoma 21
Adenocarcinoma 19
Large cell carcinoma 11
Type of resection < 0.001
Complete 109
Incomplete 16
Surgical Stage < 0.001
IA n.a
IB n.a
IIA 86
IIB 66
IIIA 33
IIIB 32
IV 19
Figure 2 - Overall survival and surgical stage.
Figure 1. Overall survival and clinical stage upon diagnosis.
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1970s and 1980s (unpublished data).
The present data showed a shift to-
wards adenocarcinoma, particularly in
the male population. This trend is
similar to previously published series
in other centers around the world.5,8-11
Our results have also shown a signifi-
cantly less favorable prognosis in pa-
tients presenting with undifferentiated
large cell carcinoma, similar to other
studies previously published.12 On the
other hand, there were no significant
survival differences between adenocar-
cinoma and squamous cell carcinoma,
results confirmed by other studies.13
The Karnofsky index (Performance
Status-KPS) effectively assessed the
general clinical condition of the pa-
tient on admission,12,14 indicating their
capability to undergo the proposed
treatment with acceptable tole-
rance.15,16 The results of the present
study showed that approximately 90%
of our patients present with a KPS of
80% or 90%. This distribution might
not exactly represent the reality of all
lung cancer population in Brazil, since
it reflects those patients referred to a
specialized cancer hospital.
Most data from the medical litera-
ture has shown that only 5% to 20%
of all lung cancer patients are asymp-
tomatic at the time of diagnosis.11,17-19
Reports in the literature have estimated
46% to 61% of patients with lung can-
cer experience significant weight loss
by the time of diagnosis.20-22 In the
present study, the results confirmed
that nearly three quarters of NSCLC
patients presented with significant
weight loss (> 10%). Several multi-
variate analyses correlate the amount
of weight lost with a worst prognosis,
for these patients are less tolerant to
aggressive treatment as well as have
poorer survival rates12,15,16,23.
Our data is comparable to world
epidemiological patterns, in which
most patients are diagnosed with more
advanced tumors (IIIB and IV).24-27 Pa-
tients that are diagnosed at an early
stage (and are therefore best indicated
for aggressive treatment and present
with the best prognosis) are less com-
mon.
As for the 1997 TNM staging, our
results show that it is an effective
method to establish therapeutic and
prognostic differences in our patient
population. Other authors have previ-
ously published similar results from
other cancer centers.28,29
Nonsmall cell lung cancer patients
undergo several surgical procedures,
including diagnostic biopsies, resec-
tion of primary tumors, and resection
of metastasis. Computed tomography-
guided cutting-needle biopsy has high
sensitivity and specificity and low
rates of complications in the diagno-
sis of indeterminate pulmonary le-
sions.30 Our data regarding operable
patients is similar to that of the litera-
ture, in which an estimated 20% to
38% of patients are candidates for
complete resection of the tumor.31-33
As shown in most series, in our
study, surgical staging proved to be
more accurate than clinical staging.34,35
It has already been shown that
complete tumor resection remains the
best therapeutic option for patients
presenting with early stage
NSCLC.31,35-39 Our results also indi-
cated that with the more detailed
preoperative imaging procedures most
patients undergoing surgery were
treated with complete surgical resec-
tion; unnecessary thoracotomies are
mostly avoided.58
In the 1990s, the role of systemic
treatment of nonsmall cell lung cancer
became clearer, with higher efficiency
and tolerance of newer drug combina-
tions.40 Indications for chemotherapy
also evolved, with several modalities
of treatment: neoadjuvant (preope-
rative), adjuvant (postoperative), ex-
clusive (in more advanced stages), and
associated with radiotherapy. In the
Hospital do Câncer A.C. Camargo,
43% of patients received some modal-
ity of chemotherapy during the course
of their disease.
Adjuvant chemotherapy, following
complete resection of the lung cancer,
is being intensively studied in multi-
ple centers around the globe, with no
convincing data yet. Our hospital par-
ticipated in a prospective, randomized
study of systemic adjuvant treatment
following complete resection of lung
tumors, stages I to IIIA (IALT), even
though adjuvant chemotherapy was
not a routine protocol in our institu-
tion. Following the recent publication
of the results of that trial,59 adjuvant
chemotherapy has been offered on a
routine basis to patients with com-
Figure 3 - Overall survival and weight loss in patients with stage IV disease (extra-CNS
metastases only).
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pletely resected nonsmall cell lung
cancer in our department.
Lung cancer chemotherapy has
changed significantly in the past dec-
ade. In the early 1990s, chemotherapy
consisted mainly of the MVP combi-
nation (mitomycin C, vinblastin, and
cisplatin).41 In more recent years, this
has been replaced with 2-drug combi-
nations. Several studies have com-
pared combinations of paclitaxel +
carboplatin with high efficiency and
tolerance,40 gemcitabine + cisplatin
also with high efficiency and without
impairing quality of life, especially in
borderline KPS,44,46 or vinorelbine +
cisplatin.40,43 These studies have led
oncologists to expand the indication
of chemotherapy to include older pa-
tients (> 70 years). Single drug chemo-
therapy or combinations that mainly
include gemcitabine or vinorelbine
have been suggested in prospective
studies, with both high efficiency and
tolerability in elderly patients.44 On
the other hand, Frasci et al.1 advocated
that cisplatin + paclitaxel, carboplatin
+ paclitaxel, and cisplatin +
gemcitabine show no substantial supe-
riority over standard treatments. This
could suggest that the addition of a
single agent to a platinum compound
could be insufficient.1 Our results show
no significant difference between dif-
ferent chemotherapy regimens used.
The question of how many chemo-
therapy cycles are adequate to achieve
maximal tumor response with minimal
side effects and complications has
been assessed in several studies, which
clearly showed no survival advantage
for patients that received more than 6
cycles of any given drug combina-
tion.45,46 Accordingly, our data showed
that only 4.2% of our patients received
more than 6 cycles of chemotherapy.
Chemotherapy in stage IV NSCLC not
metastatic to the brain has been asso-
ciated with significantly increased sur-
vival rates when compared to best sup-
portive care.47 Moreover, histopatho-
logic data may help predict the chemo-
therapy response in small cell lung
cancer.48
Radiotherapy plays a fundamental
role in the treatment of nonsmall cell
lung cancer patients. Several indica-
tions for radiotherapy have been estab-
lished, especially in patients with in-
operable intrathoracic disease. Radio-
therapy may be neoadjuvant, adjuvant,
exclusive (in patients with inoperable
localized cancers in the thorax), pal-
liative (treatment of central nervous
system or bone metastasis or tumors
that obstruct airways), or in combina-
tion with chemotherapy (for locally
advanced disease). The radiotherapy
dose depends basically on the type of
treatment (neoadjuvant, adjuvant,
etc.), tumor volume and location, as
well as general health and tolerance of
the individual patient.
Currently, the role of postoperative
radiotherapy is being evaluated world-
wide. A meta-analysis including 2128
patients from 9 different trials con-
cluded that postoperative radiotherapy
should not be routinely used for com-
pletely resected N0 or N1 patients. For
N2 patients, further investigation is
recommended.49 Sawyer showed that
postoperative radiotherapy may have
been beneficial for patients who under-
went surgical resection with N2 and
therefore had a higher local recurrence
rate.50,51 Accordingly, standard treat-
ment in our service indicates adjuvant
thoracic radiation only for patients
with completely resected N2 disease.
However, even though the treat-
ment of lung cancer has evolved, an
epidemiological study done in the Na-
tional Cancer Institute, NIH, Bethesda,
has shown that global survival of pa-
tients with lung cancer has improved
very little (at the general population
level) since the 1970s. In 1970, only
10% of the patients diagnosed with
lung cancer survived 5 years. In 1998,
this rate was only at 14%. These results
reflect the diagnosis of most patients
at advanced stages of disease and the
lack of adequate treatment options for
these patients. Our improved overall 5-
year survival rate (28%), when com-
pared with figures in the United States,
probably reflects the fact that our
group represents a selected population
from the city of São Paulo—those re-
ferred to the Hospital do Câncer A.C.
Camargo.
It is widely accepted that survival
time is intimately related to the stage
of disease at diagnosis and the disease
stage as confirmed by pathology sam-
ples taken during surgery. The histo-
logic grade of the tumor is another fac-
tor that is associated with survival
time of these patients. For squamous
cell carcinoma, staging, incomplete
tumor resection, and nucleus-cyto-
plasm ratio as well as expression of
nucleolar organizer regions identified
by an argyrophilic technique53 have
been associated with survival rates52.
Currently, complete resection of the
primary tumor (with free margins)36,52,54
and dissection of mediastinal lymph
nodes36,55 offer the best chances for
long-term survival in these patients.
A more cost-effective follow-up in
lung cancer should be performed,
which will not compromise overall sur-
vival in cases of completely resected
NSCLC, since recurrence is more often
diagnosed on the basis of symptoms
rather than by routine tests.56
From the data presented above, one
may conclude that nonsmall cell lung
cancer is a disease that requires special
attention, especially due to its high
mortality rates. Even with all available
modern treatments, the best prognosis
is for patients that undergo complete
tumor resection with lymph node dis-
section, and this is only achievable for
earlier clinical stages, demonstrating
once more the importance of early de-
tection of disease.
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RESUMO
YOUNES RN e col. Carcinoma de
pulmão não pequena células:
validação do sistema de estadia-
mento em uma única instituição
(1990-200). Rev. Hosp. Clin. Fac.
Med. S. Paulo 59(3):119-127,
2004.
OBJETIVO: Analisar o resultado
e fatores prognósticos de patients com
CPNPC admitidos em uma única ins-
tituição e correlacionar os dados com
o sistema atual de estadiamento.
MÉTODO: Setecentos e trinta e
sete pacientes com diagnóstico de
CPNPC foram admitidos ao Hospital
do Cancer A. C. Camargo entre 1990
e 2000. Todos os pacientes foram in-
cluídos em um banco de dados contí-
nuo prospectivo e seus dados foram
analisados. Após o estadiamento, uma
equipe multidisciplinar estabeleceu
decisões sobre o manejo adequado
para o caso. Variáveis analisadas inclu-
íram idade, sexo, tipo histológico, ín-
dice de Karnofsky, perda de peso,
estadio clínico, estadio cirúrgico,
quimioterapia, radioterapia e taxa de
sobrevida.
RESULTADOS: 75,5% dos pacien-
tes eram do sexo masculino. A distri-
buição dos tipos histológicos foi car-
cinoma espino celular 51,8%, adeno-
carcinoma 43,% e carcinoma indife-
renciado de grandes células 5,1%. A
maior parte apresentou perda de peso
significativa e um Karnofsky Index de
80%. O estadiamento clínico foi IA
3,8%, IB 9,2%, IIA 1,4%, IIB 8,1%,
IIIA 20,9%, IIIB 22,4%, IV 30,9%. A
ressecção total do tumor foi possível
em 24,6% dos casos. A distribuição do
estadiamento cirúrgico foi IA 25,3%,
IB 1,4%, IIA 1,4%, IIB 17,1%, IIIA
16,1%, IIIB 20,3%, IV 11,5%. Quimio-
terapia e radioterapia também foram
consideradas opções terapêuticas. A
sobrevida global de 5 anos em nosso
estudo foi de 28%, sendo a sobrevida
mediana de18,9 meses.
CONCLUSÕES: CPNPC é uma
doença que requer atenção especial,
devido aos altos índices de morbi-mor-
talidade. Melhor prognóstico está as-
sociado à ressecção completa do tu-
mor, com dissecção de linfonodos. To-
davia, isso só é possível em estadios
clínicos mais precoces.
UNITERMOS: Cancer Pulmão.
Carcinoma células não-pequenas.
Fatores prognósticos. Estadiamento.
Resultado tratamento.
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